Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
In a recent filing with the Securities and Exchange Commission, XOMA Royalty Corp (NASDAQ:XOMA) disclosed that its Chief Investment Officer, Bradley Sitko, acquired shares in the company amounting to a total value of $98,751. The transactions took place on March 21, 2025, with the stock trading near its 52-week low of $19.92 and showing a Fair Value upside according to InvestingPro analysis.
The acquisitions included 1,334 shares of common stock at a weighted average price of $20.65 per share and 2,800 depositary shares of 8.375% B cumulative stock at a weighted average price of $25.43 per share. These transactions were executed at prices ranging from $20.60 to $20.80 for the common stock and $25.42 to $25.46 for the depositary shares. The company maintains impressive gross profit margins of nearly 90%, while analyst targets suggest significant upside potential. Get comprehensive insider trading analysis and more key metrics with InvestingPro.
Following these transactions, Sitko now holds a total of 10,484 shares of common stock directly. Additionally, he holds 2,800 depositary shares directly, alongside other holdings through indirect ownership such as 829 shares by 401(k), 1,500 shares by his spouse, and 75 shares by each of his children.
In other recent news, XOMA Ltd . reported its 2024 financial results, with a GAAP EPS of ($1.65), falling short of the estimated ($0.40). The company’s full-year revenue reached $28.5 million, slightly below the forecast of $30.8 million. H.C. Wainwright maintained a Buy rating on XOMA, with a price target of $104.00, attributing the earnings miss to changes in partnered deals and related expenses. The firm’s analysts highlighted XOMA’s strong cash position of $106.8 million and the company’s commitment of $65 million to strategic transactions for long-term growth. XOMA’s revenue was bolstered by royalties and milestones, including Vabysmo, which generated $2.94 billion in sales, and Ojemda, with $57.3 million in revenue. Additionally, Miplyffa, launched in November 2024, contributed $10.1 million in revenue. The potential for high-single to mid-teen percentage royalties from Rezolute (NASDAQ:RZLT)’s drug candidate ersodetug (RZ358) presents further revenue opportunities for XOMA. The FDA recently granted Breakthrough Therapy Designation to ersodetug, which could significantly enhance XOMA’s royalty portfolio if approved.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.